Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support

What Was Tested

Researchers studied HMG (Human Menopausal Gonadotropin) in the context of endometriosis in this randomized controlled trial publication.

A questionnaire to assess the tolerability, convenience, and ease of administration of PVI and PIO given for luteal phase support was completed by infertile women diagnosed with PCOS and planning to undergo IVF.

Why It Was Studied

Administration of exogenous progesterone for luteal phase support has become a standard of practice.

Intramuscular (IM) injections of progesterone in oil (PIO) and vaginal administration of progesterone are the primary routes of administration.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, women only.

This report describes the administration preferences expressed by women with infertility that were given progesterone vaginal insert (PVI) or progesterone in oil injections (PIO) for luteal phase support during fresh IVF cycles.

The women participated in an open-label study of highly purified human menopausal gonadotropins (HP-hMG) compared with recombinant FSH (rFSH) given for stimulation of ovulation.

How the Study Was Run

In design terms this was a randomized and open-label study.

The participants were allocated by chance, so the HMG (Human Menopausal Gonadotropin) group and the comparison group should start out alike.

Being open-label, the HMG (Human Menopausal Gonadotropin) study did not mask who received what.

What Was Measured

Intramuscular (IM) injections of progesterone in oil (PIO) and vaginal administration of progesterone are the primary routes of administration.

PubMed files the paper under topics including Administration, Intravaginal, Embryo Transfer, Fertilization in Vitro, Follicle Stimulating Hormone, Infertility, Female, Luteal Phase and Menotropins.

What This Means in Plain Language

The paper is a randomized and open-label study of HMG (Human Menopausal Gonadotropin) in people with endometriosis.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Reproductive health), a journal based in England.

More context: the HMG (Human Menopausal Gonadotropin) compound page, Endometriosis research.